CORRESP Filing
TENAX THERAPEUTICS, INC.
Date: March 31, 2026 · CIK: 0000034956 · Accession: 0001193125-26-134515
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294561
Letter
Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed March 24, 2026 File No. 333-294561 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the registration statement on Form S-3 (File No. 333-294561) (the “Registration Statement”), of the Registrant, relating to the registration of certain of the Registrant’s securities, so that it may become effective on Wednesday, April 1, 2026 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. The Registrant hereby authorizes Lorna A. Knick of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna Knick at (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to our counsel via e-mail at lknick@wyrick.com.
TENAX THERAPEUTICS, INC. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 March 31, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill
Sincerely,
TENAX THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP TENAX THERAPEUTICS, INC. 101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 March 31, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed March 24, 2026 File No. 333-294561 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Tenax Therapeutics, Inc. (the “Registrant”) hereby respectfully requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the registration statement on Form S-3 (File No. 333-294561) (the “Registration Statement”), of the Registrant, relating to the registration of certain of the Registrant’s securities, so that it may become effective on Wednesday, April 1, 2026 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable. The Registrant hereby authorizes Lorna A. Knick of Wyrick Robbins Yates & Ponton LLP to orally modify or withdraw this request for acceleration. Once the Registration Statement is effective, please orally confirm the event with our counsel, Wyrick Robbins Yates & Ponton LLP, by calling Lorna Knick at (919) 865-2823. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to our counsel via e-mail at lknick@wyrick.com. Sincerely, TENAX THERAPEUTICS, INC. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer